PHARMACOLOGICAL CORRECTION OF L-NAME-INDUCED OXIDE DEFICIENCY WITH DERIVATIVES OF 3-(2,2,2- TRIMETHYLHYDRAZINIUM) PROPIONATE

This paper deals with the study of correction of L-NAME-induced endothelial dysfunction by means of 3-(2,2,2-trimethylhydrazinium) propionate derivatives. We have shown that 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives reduced the expression of NOdeficient endothelial dysfunction induced by intraperitoneal administration of N-nitro L-arginine methyl ester (L-NAME), improved the parameters of endothelium-dependent vasodilation in response to administration of acetylcholine, and reduced the coefficient of endothelial dysfunction. It was revealed that the 5-hydroxinicotinate 3-(2,2,2-trimethylhydrazinium) potassium propionate has the most pronounced endothelioprotective effect